Adjuvanted influenza vaccines by Tregoning, JS et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Download by: [Imperial College London Library] Date: 08 January 2018, At: 03:42
Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
Adjuvanted influenza vaccines
John S Tregoning, Ryan F Russell & Ekaterina Kinnear
To cite this article: John S Tregoning, Ryan F Russell & Ekaterina Kinnear (2017):
Adjuvanted influenza vaccines, Human Vaccines & Immunotherapeutics, DOI:
10.1080/21645515.2017.1415684
To link to this article:  https://doi.org/10.1080/21645515.2017.1415684
Accepted author version posted online: 12
Dec 2017.
Submit your article to this journal 
Article views: 99
View related articles 
View Crossmark data
 Publisher: Taylor & Francis 
Journal: Human Vaccines & Immunotherapeutics 
DOI: https://doi.org/10.1080/21645515.2017.1415684 
 
 
Adjuvanted influenza vaccines 
John S Tregoning1,#, Ryan F Russell1,*, Ekaterina Kinnear1 
1Mucosal Infection and Immunity group, Section of Virology, Department of Medicine, St Mary’s 
Campus, Imperial College London, W2 1PG, UK. 
*Current address: Niche Science and Technology, London. 
# Corresponding author: 
Dr John S. Tregoning, Mucosal Infection & Immunity group, Section of Virology, Imperial 
College London, St Mary’s Campus, London, UK. 
Tel +44 20 7594 3176, Email: john.tregoning@imperial.ac.uk 
Running title: Use of adjuvants in human influenza vaccines 
Abstract 
In spite of current influenza vaccines being immunogenic, evolution of the influenza virus can reduce 
efficacy and so influenza remains a major threat to public health. One approach to improve influenza 
vaccines is to include adjuvants; substances that boost the immune response. Adjuvants are 
particularly beneficial for influenza vaccines administered during a pandemic when a rapid response 
is required or for use in patients with impaired immune responses, such as infants and the elderly. 
This review outlines the current use of adjuvants in human influenza vaccines, including what they 
are, why they are used and what is known of their mechanism of action. To date, six adjuvants have 
been used in licensed human vaccines: Alum, MF59, AS03, AF03, virosomes and heat labile 
enterotoxin (LT). In general these adjuvants are safe and well tolerated, but there have been some 
rare adverse events when adjuvanted vaccines are used at a population level that may discourage 
the inclusion of adjuvants in influenza vaccines, for example the association of LT with Bell’s Palsy. 
Improved understanding about the mechanisms of the immune response to vaccination and 
infection has led to advances in adjuvant technology and we describe the experimental adjuvants 
that have been tested in clinical trials for influenza but have not yet progressed to licensure. 
Adjuvants alone are not sufficient to improve influenza vaccine efficacy because they do not address 
the underlying problem of mismatches between circulating virus and the vaccine. However, they 
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may contribute to improved efficacy of next-generation influenza vaccines and will most likely play a 
role in the development of effective universal influenza vaccines, though what that role will be 
remains to be seen.  
D
ow
nl
oa
de
d 
by
 [I
mp
eri
al 
Co
lle
ge
 L
on
do
n L
ibr
ary
] a
t 0
3:4
2 0
8 J
an
ua
ry
 20
18
 
3 
 
Introduction 
Very broadly, adjuvants are substances added to vaccines to boost immune response to the antigen. 
The first adjuvant used was an aluminium salt, Potassium Aluminium Sulphate (KAl(SO4)2.12H2O) 
often called Alum 1. When it was used in guinea pigs in 1926, it led to higher antibody titres to 
diphtheria toxoid; interestingly the beneficial effects were unexpected – Alum was used to 
precipitate the diphtheria toxoid component. Since the first use of Alum as an adjuvant, a huge array 
of substances have been tested as potential adjuvants; a small number of these have progressed 
into clinical trials and an even smaller number (six) have been included as part of licensed influenza 
vaccines. An important point to note is that adjuvants themselves are not licensed, but are licensed 
as part of the vaccine formulation. 
In this review we cover which influenza vaccines include adjuvants, why they are included, their 
mechanisms of action and their effects on vaccine immunogenicity and safety; focussing on clinical 
studies. We also evaluate some experimental adjuvants that have been tested in clinical trials but 
have not yet progressed to licensure. 
Influenza the basics 
Before focussing on adjuvants, we will quickly recap some basics about influenza virus and disease as 
they pertain to vaccination. In spite of a vaccine being available, influenza is a significant cause of 
morbidity and mortality worldwide; the WHO estimates that there are 3 – 5 million severe influenza 
cases every year, leading to 250,000 – 500,000 deaths globally 2. There is also a considerable 
economic burden associated with influenza epidemics, which can cost the European economy 
approximately €6 to €14 billion and the US economy $87.1 billion annually 3, 4. Infections follow a 
seasonal pattern, with separate waves in the northern and southern hemispheres. 
There are four types of influenza virus: A, B, C and D. Of these, the majority of human infections 
come from types A and B. Type A can be divided into 18 antigenic subtypes based on the 
haemagglutinin molecule, though of these only H1, H2, H3, H5 and H7 can infect humans and H5 and 
H7 do not currently transmit between humans. The subtypes themselves can be further subdivided 
into strains based on whether they are recognised by antibodies. These strains evolve over time, 
with small changes (antigenic drift) leading to epidemic spread and major changes (antigenic shift) 
leading to pandemic spread. These strain changes have an impact on influenza vaccines. Firstly, to 
cover the different concurrently circulating strains, influenza vaccines do not just contain a single flu 
strain they are either trivalent with two A strains and a B strain, or quadrivalent with two A strains 
and two B strains. Secondly, viral coat changes necessitate new influenza vaccines each season and 
though there are standardised processes by which the viruses in the vaccine are selected, there are 
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sometimes mismatches. Finally and most seriously, new strains of influenza with little antigenic 
overlap to existing strains emerge with extremely rapid global transmission. 
Vaccines for influenza 
Currently there are 26 licensed inactivated vaccines for influenza, of which 13 are routinely 
manufactured for each influenza season (Table 1). The vaccine manufacturers reflect a range of big 
pharma (GSK, Sanofi, Pfizer and Abbott) and smaller product focussed companies (Protein Sciences, 
Mylan, Microgen, Sinovac, Seqirus). The majority of the licensed vaccines are egg derived, and there 
are three manufacturing processes to recover and inactivate the virus: whole virus, split (where the 
virus has been disrupted by a detergent) and subunit (where the haemagglutinin and neuraminidase 
proteins have been further purified, removing other viral proteins). One manufacturer (Protein 
sciences) uses recombinant protein technology, expressing only the haemagglutinin protein from an 
insect cell line. Strikingly meta-analyses reveal very little difference in the safety or efficacy of these 
different approaches 5. In addition to the inactivated vaccines there are also three live attenuated 
vaccines with slightly different backbones: Fluenz/Flumist (AstraZeneca) uses the Ann-Arbor 
backbone whilst Ultravac (Microgen) and Nasovac (Serum institute of India) use the Leningrad 
backbone.. 
Problems with the current licensed influenza vaccines 
There are two important considerations for an influenza vaccine, immunogenicity – its ability to 
induce an immune response and efficacy – its ability to reduce influenza disease in vaccinated 
individuals. In healthy adults, inactivated influenza vaccines are mostly immunogenic (for example 6-
9). Indeed until 2015, in the EU, influenza vaccines were evaluated by serological tests alone and 
licensed on >70% of individuals achieving a haemagglutination-inhibition (HAI) titre of >1:40 and a 
four-fold increase in HAI titre in >40% of individuals. The haemagglutination-inhibition (HAI) titre is a 
functional assay which assesses the ability of the antibody to prevent the haemagglutinin protein 
from binding sialic acid. HAI>40 is a surrogate of protection defined in the 1970’s by a series of 
human influenza challenge studies 10. 
However, the ability of a vaccine to induce HAI titres against a specific virus does not necessarily lead 
to protection against the circulating strain in the subsequent flu season. Influenza vaccines have 
highly variable rates of efficacy, ranging from 10% in 2004-5 11 to 60% in 2010-11 12; the biggest 
factor being the match or mismatch between the vaccine strains and the circulating strains 13. 
Between 2000 and 2011, influenza B vaccine strains did not match circulating strains in six influenza 
seasons 14. In the autumn of 2014 increased rates of influenza activity were observed in the United 
States and this was attributed to poor vaccine effectiveness as a result of a mismatch of the H3 
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component of the current influenza vaccine to circulating strains 13. The overall effectiveness of the 
2014-15 influenza vaccine for preventing medically attended laboratory confirmed influenza virus 
was 23% 15. Early studies of influenza infections during the 2014/2015 season found that 100% of lab 
confirmed influenza A infections were A/H3N2 and of those 67% were antigenically drifted from 
A/Texas/50/2012, the reference strain used for the 2014/2015 vaccine in the northern hemisphere 
and more closely related to A/Switzerland/9715293/2013, the reference strain used for the southern 
hemisphere 15. A similar report from Canada found that of the laboratory confirmed cases of 
influenza, the majority were influenza A infections (95%), and where subtype information was 
available, 99% were found to be A/H3N2. Sequencing data available showed that 91% of the isolates 
were found to be genetically and antigenically distinct from the A/Texas/50/2012 vaccine strain 16.  
Why Adjuvants 
One potential approach to improve influenza vaccines is to include adjuvants. There are a number of 
reasons adjuvants might be included in a vaccine: 
1. Populations with poor immune responses 
Adjuvants are used to boost responses in populations with poor immune responses; this includes 
patients who are immunosuppressed due to either primary immunodeficiencies, transplant 
treatment or infection – particularly HIV. For example, the inclusion of the adjuvant AS03 improves 
the anti-influenza antibody quality in HIV positive patients 17. Likewise, the inclusion of AS03 
improved influenza vaccine responses in haemodialysis patients 18. Vaccination is also less effective 
in individuals at the extremes of age – the very young and the very old 19 – and adjuvants can help in 
these situations. Influenza causes the most severe disease in these age groups; infants (under 2 
years) and elderly patients (≥65 years) have higher influenza attack rates, more frequent influenza 
related hospitalisations and greater rates of influenza related mortality 4. Globally, influenza 
infection results in approximately 374,000 hospitalisations in 1 year old children 20. The addition of 
MF59 to an influenza vaccine induced substantially faster and higher antibody titres in children than 
a non-adjuvanted vaccine 21. There is no global estimate for influenza infection in the elderly, but 
estimates from the USA put the rate of influenza hospitalisation in elderly patients (≥65 years) at 
nearly twice that of infants 22. The addition of AS03 improved responses in young and elderly adults 
23, the addition of MF59 improved responses in subjects older than 65 24 and virosomes increased 
the response in geriatric patients 25. 
2. Boosting the immunogenicity of an antigen 
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As well as some individuals being poor at making immune responses, some antigens are less 
immunogenic than others. Many of the longstanding vaccine antigens are pathogen derived, for 
example diphtheria toxoid, tetanus toxoid and haemagglutinin. Newer vaccines often contain 
recombinant proteins and these can be less immunogenic than pathogen derived antigens. This is 
probably because the pathogen derived antigens contain trace levels of inflammatory material from 
the pathogen and some of the classical vaccine antigens may also have some inherent self-
adjuvanting property. It is of note that Flublok – the only licensed recombinant influenza vaccine –
does not contain an adjuvant, but it does contain three times as much of each haemagglutinin 
(45μg) as Aggripal (15μg) which is the Seqirus (formerly CSL/Novartis) unadjuvanted egg-derived 
inactivated virus influenza vaccine. 
3. Accelerating responses to a vaccine 
Another advantage is that adjuvants can accelerate responses to the vaccine, for example during a 
pandemic. Most vaccines require more than one administration to reach protective levels in 
recipients; the addition of an adjuvant can elevate the response to the first dose and push it over the 
protective threshold. For example HAI titres to an H1N1 vaccine were above the US and European 
licensure criteria after a single dose only when MF59 was included in both pre-clinical 26 and clinical 
studies 27. For an experimental H9N2 vaccine, antibody titres after the administration of a single 
dose of MF59 adjuvanted vaccine were similar to those after two doses of nonadjuvanted vaccine 28. 
Whilst accelerating the response may not lead to enduring immunity, it may be sufficient to protect 
individuals during the main wave of a pandemic. 
4. Dose sparing 
The inclusion of adjuvants can enable dose sparing, both for routine and pandemic vaccines. Vaccine 
antigens are expensive to manufacture and there are limited manufacturing facilities for making 
vaccines to the required good manufacturing practice (GMP) standards. The addition of AS03 led to 
a similar response to a lower dose of H5N1 antigen (3.75μg) compared to the standard 15μg dose 29. 
When alum was included as an adjuvant, equivalent responses were seen when doses of influenza 
antigen were reduced from 15μg to 6μg in both young and elderly adults 30. In a phase I study 
investigating the unlicensed adjuvant Advax (a polysaccharide particulate adjuvant derived from 
inulin) responses were equivalent between the adjuvant group that used a third of the antigen 
(15μg) and the unadjuvanted group that received 45μg influenza antigen 31. 
5. Immunomodulation 
Adjuvants can also change the quality of the immune response to antigen. The use of different 
adjuvants can change the pattern of cytokines and chemokines released, leading to the recruitment 
D
ow
nl
oa
de
d 
by
 [I
mp
eri
al 
Co
lle
ge
 L
on
do
n L
ibr
ary
] a
t 0
3:4
2 0
8 J
an
ua
ry
 20
18
 
7 
 
of different cells 32. This is particularly noticeable with T cell responses where the combination of 
different adjuvants with the same antigen can lead to very different outcomes. In a recent study the 
combination of influenza antigen with MF59 or Alum gave a strong IgG1 antibody responses 
associated with IL-5 producing T cells, whilst combination of haemagglutinin with the cationic 
liposomal adjuvant CAF01 led to a more Th1 and Th17 biased cellular response 33. Since current 
influenza vaccines primarily confer immunity through antibody, shaping the CD4 T helper response 
may not be necessary to improve protective efficacy. However, the addition of adjuvant can also 
potentially improve the quality of the B cell response and CD8 T cell responses both of which may be 
important for the development of a universal flu vaccine. Additionally, there may be subtle effects if 
the adjuvant leads to a switch in antibody subtype, when non-neutralising antibody functions, such 
as antibody dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular 
phagocytosis (ADCP), are important.  
6. Mucosal Vaccine delivery 
A final use is to enable mucosal delivery of vaccines. Through the induction of local immunity at sites 
of infection, mucosal vaccination may be more appropriate than systemic vaccination. However, 
mucosal surfaces are much harder to vaccinate for a number of reasons – they are broadly 
tolerogenic and they also have mechanical (cilia, gap junctions), chemical (mucus) and biochemical 
(proteolytic enzymes) barriers to antigen. Specific adjuvants may be required to protect the antigen 
in this environment and to induce a local immune response. One adjuvant that was licensed for this 
purpose was the heat labile enterotoxin (LT) of Escherichia coli, which was included in Nasalflu 34. 
How adjuvants work 
Before describing what is known of the mechanism of the specific adjuvants included in licensed 
influenza vaccines, it is necessary to give a brief overview of their general mechanism of action 
(reviewed in depth elsewhere 35). Fundamentally, adjuvants improve the ability of the host immune 
system to recognise the administered antigen as foreign and respond to it; beyond this simple 
description they are extremely diverse in their molecular and cellular mechanisms of action.  
The first requirement is for the vaccine antigen to be seen by the immune system. One problem is 
that soluble antigen is quickly cleared by the lymphatics and therefore is never seen by the immune 
system. Adsorbing (sticking) the antigen onto an insoluble complex (Alum) or in an oil-in-water 
emulsion (MF59/ AS03/ AF03) leads to the retention of antigen at the injection site. In theory, the 
antigen/adjuvant depot can then be sampled by antigen presenting cells, which then take antigen to 
the lymph nodes. However, recent studies in mice have shown that removing the site of the depot 
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even as early as two hours after immunisation had no negative effect on the immune response, 
suggesting that formation of a depot at the injection site is not essential 36.  
Adjuvants can also increase antigen visibility by increasing the recruitment of cells to the site of 
injection 37. The adjuvant can either recruit cells directly38 or indirectly by inducing local sentinel cells 
to release cytokines and chemokines 39. Another method of increasing antigen visibility to the 
immune system is to increase uptake by antigen presenting cells. This can also occur directly by 
acting on antigen presenting cells 40 or indirectly by inducing antigen shuttling to lymph nodes by 
other cell types 41. 
However, seeing the antigen is not sufficient to induce an adaptive immune response, cells also need 
to be licensed to respond. Some adjuvants promote dendritic cell (DC) maturation, via increased 
expression of MHCII and the co-activation markers CD80 and CD86 42. This effect is not limited only 
to DCs, as Alum and MF59 have both been shown to upregulate MHCII and CD86 expression on 
other antigen presenting cells including monocytes and macrophages 43. 
Underpinning the recruitment and activation of antigen presenting cells is the ability of adjuvants to 
stimulate the innate response, with a particular focus on triggering pattern recognition receptors 
(PRR). PRRs are expressed by innate cells and enable them to recognise infections. It covers a broad 
range of families including the Toll like receptors (TLR), Rig-like receptors (RLR) and the 
inflammasomes. Some adjuvants act directly by engaging these receptors, for example the TLR5 
ligand flagellin 44. However other adjuvants, particularly particulate adjuvants, act more indirectly by 
inducing local damage which is in turn detected by inflammasome complexes 45, though the exact 
pathway by which this occurs is not fully characterised. 
For the effective induction of an antibody response, there needs to be an interaction between T and 
B cells. B cells do not directly interact with antigen presenting cells, but they do respond to some of 
the same signals 46, so it may be that adjuvants activate them in this way. Alternatively, improving 
the T cell quality with adjuvant, for example increasing the number of T follicular helper cells 47, may 
lead to improvement in the antibody response.  
Whilst many of the adjuvants that are used have been developed empirically, greater insight about 
the induction of the innate immune response and how that shapes the adaptive immune response 
has led to immunologically designed adjuvants, for example MPLA targeting TLR4 which is 
incorporated into AS04. However, for many of the adjuvants in wide use, mechanistic knowledge is 
incomplete, but this doesn’t prevent vaccine licensure; provided a vaccine works and is safe, the 
mechanism of action is a secondary consideration. 
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Adjuvants in licensed influenza vaccines: characterisation and mechanism 
Alum is the most commonly included adjuvant in influenza vaccines, but even then is only included 
in five vaccines. The other adjuvants used are virosomes (Inflexal V), MF59 (FluAd), AS03 
(Pandemrix). AF03 was licensed for as part of Humenza, but this product was never marketed. Heat 
labile enterotoxin (LT) was licensed as part of Nasalflu, but this has been withdrawn. 
 Alum 
Alum is the oldest and most widely used adjuvant. Though it should be noted that the description 
Alum, which strictly refers to KAl(SO4)2 only, often covers a broad range of Aluminium salts, including 
aluminium phosphate and aluminium hydroxide. Strikingly the immunological mechanism of action 
of Alum is still not entirely understood 48-50. Recent studies have suggested that the formation of an 
antigen depot is not sufficient to explain the mechanism of alum36. Sensing of alum appears to be 
inflammasome mediated via uric acid crystals leading to the release of interleukin-1β (IL-1β) 45, this 
was supported by studies where treatment with uricase reduced alum induced inflammation 51. 
However patients receiving the anti-IL-1β monoclonal antibody Canakinumab had no difference in 
their response to adjuvanted influenza vaccination, suggesting that the effect of Alum is partially IL-
1β independent 52. Other studies have identified a role for DNA release following alum induced 
necrosis of local cells, this DNA is then sensed by the STING pathway 53. However it is sensed, alum 
leads to local inflammation of neutrophils via the chemokines CXCL2 and CXCL1 51 and macrophages 
via CCL2 and CCL4 54. The cells that reach the vaccination site either shuttle antigen to antigen 
presenting cells or are capable of acting as antigen presenting cells in their own right, with in vitro 
data suggesting that Alum improves antigen uptake 55. Alum activated antigen presenting cells tend 
to shift the response towards a T helper 2 phenotype 56, though it is not clear how. 
 MF59 
MF59 is an oil-in-water emulsion which was originally designed by Chiron to meet the need for an 
adjuvant which could induce good immunogenicity to purified antigen vaccines 57. At the time of 
MF59 development, Alum remained the gold standard adjuvant, but it was ineffective as an adjuvant 
for new recombinant technologies. MF59 was designed using the principles of Freund’s incomplete 
adjuvant, a mineral oil–in-water emulsion which although tested in human influenza vaccination 58, 
was deemed too reactogenic for regular use 59. MF59 contains squalene, polysorbate 80 and 
sorbitan trioleate. Squalene was chosen as the oil component as it is a naturally occurring oil found 
in large quantities in human tissues.  
The mechanism of MF59 action has been well studied 60. Whilst antigen can form complexes with 
MF59, there is no evidence that depot formation is required for MF59 function as it is quickly cleared 
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from the site of immunisation 61. As with alum, the innate sensing pathways involved in the 
detection of MF59 have not been fully identified: it appears to act independently of NLRP3 62, 63, 
though MyD88 62 and CARD 63 appear to play a role. At a molecular level, MF59 induces a specific 
gene signature that is distinct to Alum, with enrichment in four KEGG categories: cytokine-cytokine 
receptor interaction, host–pathogen interaction, defense immunity protein activity and the type I 
IFN response 37. MF59 induces a distinctive pattern of cytokines after immunisation 64 including the 
monocyte chemoattractant CCL2, and the neutrophil chemoattractants CCL3 and CXCL8 43. These are 
associated with the recruitment of neutrophils to the site of immunisation that transport the antigen 
to the lymph nodes 41. Interestingly, the mechanism of action of MF59 requires the whole 
formulation; none of the individual components induce an adjuvant effect 65. MF59 has also been 
shown to activate DCs 55, 66 and other antigen presenting cells including monocytes and macrophages 
43. MF59 also induces a shift in the T cell response towards Th2. Both IL-4 and STAT-6 signalling are 
required for its mechanism and there is a shift towards IL-5, evident even after infection of MF-59 
immunised animals 64. How MF59 administration leads to the release of these specific chemokines 
and cytokines is not known. 
 AS03 
AS03 is an oil-in-water adjuvant, developed by GSK as part of a broader Adjuvant System which has 
multiple members 67. AS03 contains squalene, DL-α-tocopherol and polysorbate 80. Variants of AS03 
have been produced, based on the amounts of squalene, DL-α-tocopherol and polysorbate 80: AS03A 
has 0.86 mg polysorbate 80, 10.69 mg squalene and 11.86 mg α-tocopherol, whilst AS03B has half 
the quantities of these components. The inclusion of α-tocopherol, a bioavailable form of vitamin E, 
has been argued to boost the immunogenicity of AS03. In order to exert an adjuvant effect, AS03 
needs to be administered at the same time as the antigen 68. AS03 works in a similar fashion to 
MF59, by engaging the innate immune system leading to cellular recruitment and antigen uptake at 
the site of immunisation 69. At a molecular level AS03 administration led to the upregulation of MX1 
and STAT1 gene expression 70. Following AS03 delivery, both neutrophil and monocyte 
chemoattractants are induced 68. The administration of AS03 leads to the upregulation of CD4 T cell 
responses and IFNγ release 71. 
 AF03 
AF03 (Sanofi Pasteur) is an oil-in-water adjuvant containing squalene, montane 80 and eumulgin b1 
ph. The manufacture of AF03 is slightly different to MF59 and AS03, using phase inversion 
temperature emulsification process 72. But since it is also an oil-in-water adjuvant it is likely to have a 
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similar mechanism of action to other oil-in-water adjuvants. It is included in the Humenza vaccine 
but this has never been marketed. The mechanism of AF03 has not been characterised.  
 Virosomes 
Inflexal V uses virosomes in its formulation. Virosomes, sometimes referred to as liposomes, are 
based on lipid droplets 73, most commonly using phospholipids. Lipids in aqueous solution can 
spontaneously form bilayers generating a vesicle that encapsulates a volume of aqueous solution 
inside. Influenza virosomes incorporate influenza antigen onto the surface of the vesicle and so 
mimic a virus; as such virosomes can be considered as a type of viral like particle (VLP). The physical 
properties of these particles are critical in their efficacy 74. By mimicking a virus, virosomes can assist 
with antigen uptake into antigen presenting cells, cell activation and trafficking within the lymph 
system. Virosomes with surface exposed antigen can also boost antibody responses by improving 
the 3D structure of the antigen, increasing antigen density, which leads to greater cross linking of B 
cell receptors. Whilst the virosomes used do not have influenza genetic material incorporated, there 
is scope to incorporate this or other PAMPs and therefore deliver immune activators directly to the 
B cells 46. 
Impact of adjuvants on the immune response to flu 
The inclusion of an adjuvant increases anti-influenza antibody responses. When compared against 
unadjuvanted vaccines, virosome adjuvanted vaccines were more immunogenic in both children 75 
and the elderly 25. In children, the addition of MF59 induced greater antibody 76 and cellular 77 
responses than vaccine without adjuvant. MF59 also induced a better response in immune naïve 
individuals 78 to a potential pandemic antigen. Likewise the inclusion of the AF03 adjuvant boosted 
responses compared to unadjuvanted vaccine in 6-35 month old children 79. H5N1 influenza vaccine 
formulated with AS03 induces stronger B and T-cell responses than vaccine alone 80. When MF59 
was compared directly against virosomes, it led to a significantly greater number of elderly patients 
seroconverting (fourfold increase in antibody titre) 24, but both have been shown to have efficacy 
against influenza infection in the elderly 81. Comparisons have also been performed between AS03, 
MF59 and unadjuvanted H7N9 antigen; both the adjuvants induced seroconversion in significantly 
more patients than no adjuvant 82, in this study AS03 inclusion led to a higher antibody titre. A 
couple of meta-analyses indicated that inclusion of MF59 increased Haemagglutination inhibition 
(HI) titres by 1.14-1.4 fold 5, 83, but it was argued that this would not have a big impact on efficacy, as 
based on human challenge studies 10, this difference in HI titre is not large enough to have an effect. 
Safety/ Tolerability of adjuvanted flu vaccines 
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In general adjuvants are well tolerated, though they may increase some local site symptoms, 
particularly injection site pain. Two Phase III studies of AS03 adjuvanted H5N1 have been performed 
covering 10,000 adults 84, 85. In these studies, the adjuvanted vaccine solicited local and general 
symptoms more frequently, including pain, fatigue, headache and myalgia. Immunisation of children 
with an AS03 adjuvanted vaccine was also associated with transient injection site pain 86. Similar 
results were seen with an AS03 adjuvanted H1N1 vaccine, the most frequently reported symptom 
was injection site pain 87, and local and general symptoms were reported more frequently for AS03-
adjuvanted H1N1 vaccine recipients than for controls 88, 89. In children, the incidence of some 
reactions, especially fever (axillary temperature ≥37.5°C), increased after the second dose 90. A 
meta-analysis of MF59 usage in clinical trials in elderly adults suggested that local reactions were 
slightly more common for vaccine with adjuvant, but fever was very uncommon in either group 91. A 
retrospective review over the lifespan of the virosome adjuvanted vaccine, 92 Inflexal V 93, suggest 
that virosomes are well tolerated. 
When adjuvants didn’t work:  
However, there have been notable cases where adjuvanted influenza vaccines have had to be 
withdrawn (Nasalflu) or the recommended usage altered (Pandemrix). Separating the specific 
contribution of adjuvant to the adverse effect is complicated as they are always administered in 
combination with the antigen. However, it is likely that the adjuvant played a role in the adverse 
effects seen. There are a range of possible mechanisms  by which the inclusion of an adjuvant might 
have increased the incidence of severe adverse effects including increased inflammation caused by 
the adjuvant, as seen with LT adjuvanted Nasalflu, or altered responses to the antigen including 
increased immunogenicity of sub-dominant epitopes, as possibly seen with AS03 and narcolepsy. 
AS03 adjuvanted H1N1 vaccine and narcolepsy. 
One of the vaccines produced in response to the emergence of the 2009 H1N1 pandemic virus was 
an AS03 adjuvanted H1N1 vaccine, marketed by GSK as Pandemrix. Approximately 90 million doses 
of AS03-adjuvanted H1N1 vaccine were administered worldwide during the 2009–2010 H1N1 
pandemic. After the vaccination campaign had been completed, cases of the rare sleeping disorder, 
narcolepsy, were reported in Sweden and Finland 94; this was particularly seen in individuals with the 
HLA-DQB1*0602 haplotype. A retrospective study in the UK also reported an increased risk of 
narcolepsy in ASO3 adjuvanted pandemic A/H1N1 2009 immunised children 95. The cause of vaccine 
associated narcolepsy is uncertain, but one suggestion is that there was an increased frequency of 
antibodies to hypocretin receptor 2 in the sera of immunised patients 96. Since the antibodies were 
cross reactive with a fragment of the influenza nucleoprotein, one suggestion that it was a 
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combination of HLA haplotype and nucleoprotein rather than AS03 per se 97. Subsequently the use of 
Pandemrix has been restricted to people over 20 years of age. 
Heat labile enterotoxin adjuvanted vaccine and Bell’s Palsy 
Nasalflu (Berna Biotech) was an intranasally delivered virosomal influenza vaccine adjuvanted with 
the heat labile enterotoxin of E. coli. In the pre-licensure trials covering 1,218 volunteers no adverse 
effects were reported. However, in the first seven months after licensure, 46 cases of Bell’s Palsy 
were reported. In a subsequent matched case-control study, the risk of Bell’s Palsy was 19 times the 
risk of controls, or 13 excess cases per 10,000 vaccinees 98. This appears to have been driven by the 
inclusion of heat-labile enterotoxin as an adjuvant; a study using a genetically detoxified mutant also 
led to transient Bell’s Palsy 99. One suggested mechanism is that LT undergoes retrograde neuronal 
uptake 100 via the olfactory nerve leading to uptake of the adjuvant and possibly the vaccine by the 
nerve cell 101, which may then lead to inflammation of the nerve. 
Future of flu vaccines and adjuvants  
Clinical trials of adjuvanted flu vaccine studies in humans have a long history, with one of the earliest 
studies being performed by one of the founders of modern vaccinology, Maurice Hilleman, who used 
a stabilised water-in-oil formulation in 1967 102. The appetite for new adjuvants has ebbed and 
flowed, at times they are heralded as the next big thing that will change vaccinology, but at other 
times they are seen as a red herring. The number of experimental adjuvants that have been used 
pre-clinically is too large for the scope of this review. Whilst there is a huge range of pre-clinical 
vaccine adjuvants in development, a smaller number have made it into clinical trials (Table 2). There 
are a number of reasons why the pre-clinical adjuvants have not moved forwards: some of them 
simply do not work, some have limited efficacy in animal models that fails to translate into human 
responses, some would be too expensive to manufacture for a mass market and some are just too 
weird and wonderful to have a pathway to commercial and clinical development. There have been 
cycles of development of the substances used, from empirical approaches to immunological design 
based on better understanding of immune sensing. The adjuvants that have been tested clinically fall 
into four broad categories: toll like receptors (TLR) ligands, formulation, cytokines and 
immunostimulators with unknown mechanism. Where results are reported, experimental adjuvants 
have mostly increased the antibody response to influenza, though in some cases the increases have 
been marginal. 
TLR Ligands 
Increased understanding of the events initiating the immune response have led to more targeted 
adjuvant approaches 103. The TLRs are a family of evolutionarily conserved pattern recognition 
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receptors that recognise conserved biochemical motifs that are common in pathogens. Over recent 
years, the TLRs have been the focus of immunopotentiator development for use as both 
prophylactic and therapeutic vaccine adjuvants 104, 105. The most widely studied Toll like receptor, 
TLR4, recognises lipopolysaccharide (LPS), a major component of the outer membrane of gram 
negative bacteria. In its native form LPS is too inflammatory to be used as part of a vaccine, but a 
number of modified versions have been used, including monophosphoryl lipid A (MPLA) and 
Glucopyranosyl Lipid Adjuvant (GLA). MPLA is present in two adjuvants that are part of licensed 
vaccines (AS01 and AS04). GLA has been successfully tested in a clinical trial for a potentially 
pandemic H5 strain of influenza 106. Many of the other TLRs have also been targeted for adjuvants to 
boost influenza responses, for example, topical application of imiquimod, a TLR7 agonist 107 which 
has already been licensed for the treatment of genital warts. Likewise, agonists of TLR3 
(rintatolimod) 108 and TLR9 (CpG oligodeoxynucleotides) 109 have also been tried. Fusions of antigens 
and the TLR5 agonist flagellin have also been developed 44, 110. 
Formulation 
The second class of adjuvants in development are those that broadly effect vaccine formulation. 
They are either oil-in-water variants, with similarities to MF59/AS03 or liposomal, with similarities to 
virosomes. Formulations adjuvants work in part by delivering the vaccine antigen to the correct cell 
types and in part by causing some local inflammation. Often the formulation incorporates directly 
inflammatory material. 
Cytokines 
Cytokines are cell signalling molecules used by the immune system to program the response of other 
cells. Cytokine induction is a key mechanism of action of many adjuvants and so some studies have 
looked at directly incorporating cytokines into vaccines to improve responses. These have included 
the T cell activator IL-2 111, the dendritic cell activator GM-CSF 112 or type I interferon 113. These 
approaches only had a modest effect and the cost of generating a second protein for inclusion in a 
vaccine makes these unlikely candidates for any onward development. One interesting variant on 
this is DNA vaccines, where DNA encoding antigen is used as the immunogen 114. In these vaccines, 
DNA encoding cytokines has been included to boost the immune response for example IL-12 115 and 
GMCSF 116. A number of clinical trials of DNA encoded influenza vaccines have been performed, but 
the immune response to them has been modest. An alternative nucleic acid based approach is to 
deliver the immunogen as RNA. Both DNA and RNA vaccines will have some inherent adjuvant 
qualities, which will boost the immune response to the expressed antigen, but may limit antigen 
expression in the first place. 
D
ow
nl
oa
de
d 
by
 [I
mp
eri
al 
Co
lle
ge
 L
on
do
n L
ibr
ary
] a
t 0
3:4
2 0
8 J
an
ua
ry
 20
18
 
15 
 
Immunostimulators with unknown mechanism 
This covers a diverse range of substances that can boost the immune response to antigen, but 
without a clear understanding of the immunological mechanism. The likelihood is that they cause 
some local disruption of cell membranes leading to the release of ‘danger signals’ triggering a local 
innate immune response. The clinical studies for these compounds have reported limited increases 
in immune response. 
Of the adjuvants in development, we would speculate that the most likely to progress forward are 
the TLR based adjuvants. This is because the mechanistic understanding here is the greatest, they 
are relatively cheap to manufacture and the research on them is the most mature. Indeed a TLR4 
ligand (MPLA) has already been included in licensed vaccine adjuvants – AS01 and AS04. 
Adjuvants in licensed vaccines other than influenza 
In addition to those that have been tested in early phase clinical trials, there are adjuvants that have 
been included in licensed vaccines that may be included in influenza vaccines in the future. GSK has 
two other adjuvant formulations that are used in licensed vaccines. AS01 is a liposomal adjuvant 
containing the TLR4 ligand monophosphoryl lipid A (MPLA) and the saponin QS-21 and is part of the 
anti-malaria vaccine Mosquirix. AS01 was designed specifically to boost cell-mediated immunity, 
with a particular focus on CD8 T cells 117. A vaccine containing this adjuvant has now completed 
phase III clinical trials 118, 119, conferring medium-term moderate protection to malarial disease. AS04, 
which contains Alum and MPLA, is used in Cervarix (human papilloma virus) and Fendrix (Hepatitis 
B). AS04 was first used in Fendrix in 2005 and is currently licensed in Europe 120.  
Future of adjuvanted flu vaccines 
The biggest question is whether any of the adjuvants in development will be included in a licensed 
commercial product. There are two hurdles to overcome – the cost of manufacturing the adjuvant to 
GMP standard at a scale required for influenza vaccine and the risk of an unforeseeable adverse 
effect occurring when the vaccine is deployed at a population level. Realistically for the current 
generation of influenza vaccines, particularly in the face of existing adjuvants from the major vaccine 
manufacturers, in our opinion it is unlikely that a new adjuvant will be included in a seasonal 
influenza vaccine. However, there is still scope for research into adjuvants to support the next 
generation of influenza vaccines. Speculatively this could focus on the following areas: 
1. Stabilising the haemagglutinin stem region. The holy grail of influenza vaccine research is 
the ‘universal flu vaccine’. This would be one vaccine that covers all current and future strain 
variations. One speculative approach to achieve this extremely difficult goal has been to 
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target the stem region of the haemagglutinin antigen 121. Very approximately speaking, 
haemagglutinin is shaped like a mushroom, with a head and a stem. The head is 
immunologically dominant, but is also the region that changes the most, the stem is more 
conserved across different flu stains 122. Potentially antibodies raised against this region may 
be able to cross neutralise different strains of virus. Whilst natural infection does raise some 
anti-stem antibodies 123, raising them with a vaccine has proved tricky. One application of 
adjuvants could be to stabilise structures that expose the stem region without the head 
domain. 
2. Universal T cell vaccines. Whilst most influenza vaccine research has focussed on vaccines 
that can induce antibody, an alternative might be to induce T cells. Adjuvants that stimulate 
T cell responses e.g. CAF09 124 or IC31 125 may potentiate stronger CD8 responses which may 
be beneficial. Because they often recognise conserved regions of influenza, T cells can 
possibly offer better cross neutralisation 126, 127. There is a history of pre-clinical studies 
indicating that cross protection can be achieved with CD8 T cells 128 and in human challenge 
studies T cells correlated with viral shedding 129. More recently, studies have shown that 
individuals with elevated T cell responses experienced less severe disease on exposure to 
pandemic influenza 130. Interestingly CD4 T cells have also been shown to correlate with 
protection against challenge 131. 
3. Mucosal protection. It is becoming clear that local, mucosal immune responses may be 
more protective than systemic responses. For example, we have recently shown that local 
IgA is a correlate of protection against influenza challenge 132. Likewise lung resident T cells 
(Trm) correlate with protection against challenge in both mouse 133 and human infection 
studies 134. However, mucosal vaccination has to date been sub-optimal, the addition of an 
adjuvant may improve mucosal responses. The addition of an adjuvant to a mucosal 
influenza vaccine is challenging as the only licensed mucosal vaccine containing an adjuvant 
(LT/ NasalFlu) had to be withdrawn due to the association with Bell’s Palsy 98. 
4. Protection in diverse age groups. One of the major priorities for an adjuvanted influenza 
vaccine is the ability to induce a strong response in individuals who are most susceptible to 
infection – the elderly and the very young 19. It is likely that since the reasons vaccines are 
less effective in these age groups are different, different approaches will be required. The 
use of GLA with an RSV antigen improved anti-RSV responses in adults over the age of 60, 
suggesting that it may also be effective with influenza 135, 136. Studies in children are more 
complex to perform, with a greater risk of unforeseen complications, but this doesn’t stop 
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there being a need for infant specific adjuvants. AS02 has been tested in infants (under 1 
year of age) in the context of a malaria vaccine, increasing T cell responses 137.  
5. Pandemic protection. Of all the viruses, influenza remains one of the most likely to cause a 
pandemic. This has occurred multiple times, most recently with the emergence of the 2009 
H1N1 strain. Under these circumstances, the addition of an adjuvant would enable faster 
responses and dose sparing to achieve greater coverage. Any of the adjuvants described in 
this review could potentially perform this function and a number of clinical trials have been 
performed to pre-test adjuvanted vaccines in this capacity. There are also a number of 
pandemic vaccines that are pre-licensed to cover the emergence of new strains.  
6. Boosting recombinant and neoantigens. The majority of the current influenza vaccines are 
egg derived and therefore contain some degree of other viral material which may boost the 
immune response to the antigens. However, recombinant antigens, especially those that 
have been specifically designed using structural vaccinology approaches, may need boosting 
by adjuvant 138. This is particularly important for neoantigens from newly emerged pandemic 
influenza strains for which there is no pre-existing adaptive immunity, notably avian derived 
antigens have lower immunogenicity in humans. 
7. Resetting original antigenic sin. An individual’s influenza exposure history over life is 
complex with a mixture of vaccination and natural infection. This repeated exposure shapes 
the antibody and T cell responses, often focussing the response on immunodominant 
regions 139. The concern is that original antigenic sin may reduce the ability to generate 
responses to novel antigens. It is possible that an adjuvant could reset the B cell response or 
present new antigens in such a way that B cell memory is altered. 
8. Altering isotype for maternal vaccination. One usage of influenza vaccines is maternal 
immunisation, this protects both the mother and the offspring in early life by passive 
antibody transfer. During pregnancy, maternally derived antibodies are actively transported 
through placenta from the mother to the foetus, which can provide passive immunity for 
infants up to 6 months against infection 140. There are four subclasses of human IgG (IgG1-4). 
Placental transfer of IgG depends on the subclass, IgG1 is best followed by IgG4, IgG3 and 
IgG2 141. Since adjuvants can alter the IgG subclass 33, potentially the inclusion of a minimally 
inflammatory adjuvant that preferentially boosts the IgG1 response could boost the amount 
of antibody transferred to the foetus. 
Conclusion 
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In general, adjuvanted influenza vaccines have a good safety profile and improve the immune 
response to vaccine antigens. However the addition of an adjuvant may not address the problems 
with the current generation of influenza vaccines. The problem with these influenza vaccines is not 
immunogenicity, for the majority of healthy adults influenza vaccination is sufficiently immunogenic. 
The problem is that the influenza virus evolves away from the vaccine antigen and the induced 
response is protective against the wrong virus. Changing the magnitude of the response with 
adjuvant would not necessarily address the problem. Indeed, there are costs that argue against the 
routine incorporation of adjuvants in seasonal influenza vaccines. This includes the manufacturing 
cost of an extra component to the required good manufacturing practice (GMP) standard, the 
elevated frequency of low severity adverse effects after adjuvanted vaccination and finally the small 
risk of low frequency unexpected severe adverse effects, such as Bell’s Palsy after LT adjuvanted 
vaccination or narcolepsy after AS03 adjuvanted vaccination. However, there are two current usages 
that warrant the addition of an adjuvant, firstly vaccination of elderly patients with sub-optimal 
immune responses and secondly pandemic vaccination where fast responses to smaller doses of a 
previously unseen antigen are required to maximise coverage. Looking forwards, novel adjuvants 
may also help in the drive for a universal influenza vaccine by stabilising antigens, boosting 
responses to recombinant antigens, or redirecting the immune response towards either a local or a 
cellular response.  
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Table 1. Licensed vaccines for influenza. Trivalent vaccines contain three strains, usually two 
influenza A (currently a representative H1N1 and H3N2 strain) and an influenza B strain (either a 
Yamagata lineage or Victoria lineage depending on what is currently circulating). Quadrivalent 
vaccines contain four strains two A and two B. Pandemic vaccines are pre-licensed in anticipation of 
that strain becoming more prevalent. Apart from Flublok which is recombinant protein, the majority 
of vaccines are egg derived and either whole virion, split (where the virus has been disrupted by a 
detergent) and subunit (where the haemagglutinin and neuraminidase proteins have been further 
purified, removing other viral proteins). 
Product Name Vaccine type Manufacturer Adjuvant Currently in Use? Age given 
Influvac Subunit, inactivated, 
Trivalent 
Abbot Biologicals 
(Distributor Mylan) 
None Still in Use ≥6 months, higher doses 
for those over 3 years 
Fluenz live attenuated virus, 
Quadrivalent 
AstraZeneca None Still in Use ≥24 months  
Nasalfu Subunit, inactivated 
Trivalent 
Berna Biotech Virosome 
Heat Labile 
enterotoxin (LT) 
Not in use   
Inflexal V Subunit, inactivated 
Trivalent 
Crucell (formerly Berna 
Biotech) 
Virosome Unclear ≥6 months, higher doses 
for those over 3 years 
Panvax/ Panvax Junior Split virion, inactivated 
Pandemic H1N1 
CSL Ltd None Not in use ≥6 months  
Fluvax/ Fluvax Junior Split virion, inactivated CSL Ltd Non Still in use ≥5 years 
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Trivalent 
Pandemrix Split virion, inactivated, 
Pandemic H1N1 
GSK AS03 Not in use ≥6 months, higher doses 
for those over 10 years 
Daronrix Whole virion, inactivated, 
Pandemic H5N1 
GSK AlPO4 & Al(OH)3 Not in use ≥18 years 
Prepandrix Split virion, inactivated, 
Pandemic H5N1 
GSK AS03 Still in Use  ≥18 years and double dose 
for >80 years 
Arepanrix Split virion, inactivated, 
Pandemic H1N1 
GSK AS03 Not in use ≥6 months  
Fluarix Split virion, inactivated, 
Quadrivalent 
GSK None Still in use ≥3 years 
Q-Pan H5N1 Split virion, inactivated, 
Pandemic H5N1 
GSK  AS03 Still in use ≥6 months  
Orniflu Subunit, inactivated, 
Pandemic H5N1 
Microgen Russia Al(OH)3 Still in use  ≥18 years 
Imuvac Subunit, inactivated, 
Trivalent 
Mylan None Still in Use ≥6 months  
      
Celtura Subunit, inactivated, 
Pandemic H1N1 
Novartis MF59 Pandemic only ≥6 months  
Focetria Subunit, inactivated, 
Pandemic H1N1 
Novartis MF59C.1 Not in use ≥6 months  
Fluval-AB/Fluval-P/Fluval-K Whole virion, inactivated, 
Trivalent 
Omnivest AlPO4 gel Still in Use ≥6 months  
Enzira Split virion, inactivated, 
Trivalent 
Pfizer None Still in Use ≥5 years 
Flublok Recombinant protein, 
Trivalent 
Protein Sciences None Still in Use ≥18 years 
Emerflu Split virion, inactivated, 
Pandemic H5N1 
Sanofi Pasteur AlPO4 Not in use ≥18 years when pandemic 
flu declared 
Humenza Split virion, inactivated, 
Pandemic H1N1 
Sanofi Pasteur AFO3 Not in use ≥6 months  
Fluzone Quadrivalent Split virion, inactivated, 
Quadrivalent 
Sanofi Pasteur None Still in Use ≥3 years 
Intanza Split virion, inactivated, 
Trivalent 
Sanofi Pasteur None Still in Use ≥60 years 
Agrippal Subunit, inactivated, 
Trivalent 
Seqirus None Still in Use ≥6 months  
Optaflu Subunit, inactivated, 
Trivalent 
Seqirus None Not in use ≥6 months  
FluAd Subunit, inactivated, 
Trivalent 
Seqirus MF59C.1 Still in Use ≥65 yrs 
Panflu Whole virion, inactivated, 
Pandemic H5N1 
Sinovac Al(OH)3 Still in Use  ≥18 years 
 
Table 2. Human clinical trials with experimental adjuvants (Pubmed influenza vaccine adjuvant: 
Clinicaltrials.gov condition influenza, other terms adjuvant) 
Adjuvant Name Adjuvant Class Adjuvant Description Associated 
CT.gov ref 
Sponsor/ Associated Study 
Date 
Efficacy? Related 
Paper 
GLA TLR TLR4 ligand NCT01147068. IDRI 2012 GLA improved serum 106 
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 antibody response 
Imiquimod 
ointment 
TLR TLR7 agonist NCT02103023 University of Hong Kong 2014 Increased antibody 107 
Aldara/ 
Imiquimod 
TLR TLR7 topical agonist NCT02960815 University of Lausanne 2016 None reported  
Rintatolimod TLR TLR3 agonist (plus LAIV) N/A University Alabama/ 
Hemispherx 
2014 No comparator 108 
Vax128 TLR Haemagluttinin-flagellin 
fusion (TLR 5 agonist) 
NCT01172054 Vaxinnate  Reactogenic, no control for 
efficacy 
44 
VAX102 TLR Matrix protein-flagellin 
fusion 
N/A Vaxinnate 2011 Reactogenic 110 
CpG TLR TLR9 agonist N/A Coley Pharmaceutical 
Group 
2004 No effect 109 
IC31 TLR TLR9 agonist + uptake 
peptide 
N/A Intercell/ Novartis 2008 Data not published  
ISS TLR TLR9 agonist N/A Dynavax 2011 Data not published  
JVRS-100 Formulation Cationic lipid/ DNA 
complex 
NCT00662272, 
NCT00936468 
Colby Pharmaceutical 2008 None reported  
MAS-1 Formulation Nanoparticular, emulsion NCT02500680 
NCT01623232 
Nova 
Immunotherapeutics/ 
Mercia 
2015 None reported  
Vaxisome Formulation Cholesterol liposome NCT00915187 NasVax 2009 None reported  
PAL Formulation Papaya mosaic virus 
nanoparticle 
NCT02188810 Folia Biotech 2014 None reported  
Matrix-M1 Formulation Saponin, cholesterol and 
phospholipid (ISCOM) 
NCT01897701 
NCT01444482 
Novavax 2013 Increased antibody 142 
Montantide Formulation Water in oil NCT00877448 BiondVax Ltd 2009 Adjuvant increased 
response 
143 
Proteosome Formulation Bacterial hydrophobic 
outer membrane proteins 
NCT02522754 hVIVO 2015 No comparator 144 
W805EC Formulation Nanoemulsion delivered 
intranasally with Fluzone 
N/A NanoBio Corporation 2012 No difference with antigen 
alone 
145 
ISCOM Formulation Immune stimulating 
complexes 
N/A Erasmus 2000 More rapid antibody 
response 
146 
Liposome Formulation Oligolamellar 
phospholipid 
N/A St Louis University 1995 Improved CD8 response 147 
NanoStat, 
NB1008 
Formulation Emulsion NCT01333462/ 
NCT01354379 
NanoBio 2011 No results reported  
Type I 
Interferon 
Cytokine Cytokine delivered 
mucosally 
NCT00436046 Baylor College 2007 No effect 113 
 
IL-2 Cytokine Cytokine N/A Hebrew University, 
Jerusalem 
2003 Boosted antibody 
responses 
111 
 
GM-CSF Cytokine Cytokine N/A Emory University 2002 No effect 112 
LT Patch Immunostimulator Heat labile enterotoxin NCT00908687 Intercell 2009 Boosted primary response 148 
 
BCG Immunostimulator Nonspecific immunity, 
delivered 14 days before 
vaccine 
N/A Radboud Institute for 
Health Sciences 
2015 Increased response 149 
 
Advax Immunostimulator Polysaccharide/ delta 
Inulin 
ACTRN1261200
0709842 
Vaxine 2015 Increase in B cell response 150, 151 
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OM-85 BV Immunostimulator Mixed Bacterial lysate N/A Fondazione IRCCS 2014 No effect 152 
OMP-TIV Formulation/ 
Immunostimulator 
Meningococcal outer 
membrane proteins 
N/A GSK 2011 No antigen alone control 153 
Mimopath/ 
FluGEM 
Formulation/ 
Immunostimulator 
Bacterium Like Particles N/A Mucosis 2012 None reported  
Nasalflu/ LT Formulation/ 
Immunostimulator 
Virosomal-Subunit 
adjuvanted LT 
N/A Berna Biotech 2000 Effective but 46 cases Bell’s 
Palsey 
98 
sLAG-3 
(IMP321) 
Immunostimulator MHC II ligand N/A Immutep 2006 No effect on antibody, 
increased T cell response 
154 
QS21 Immunostimulator Saponin N/A Baylor 2006 No effect 155 
DHEAS Immunostimulator Dehydroepiandrosterone 
sulphate 
N/A Paradigm Biosciences 1997 No effect 156, 157 
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